Tyrosine kinase inhibitors against the receptors of vascular endothelial growth factor (VEGFR), epidermal growth factor (EGFR) and the platelet derived growth factor (PDGFR) are increasingly used in the treatment of progressive cancers. However, the expression of these receptors especially in lung metastases has not been examined. Tissue specimen from 35 lung metastases of 33 patients with renal cell carcinoma (ns8), sarcoma (ns10), colorectal carcinoma (ns6), otolaryngologic carcinoma (OLC, ns4), testicular and endometrial cancer (ns1 each), malignant melanoma (ns1), adrenal cancer (ns2), malignant fibrous histiocytoma and malignant peripheral nerve sheath tumor (ns1 each) have been immunohistochemically tested for the expression of PDGFR ayb, VEGFR and EGFR. None of the patients had been pretreated with angiogenic inhibitors prior to metastasectomy. PDGFRa was expressed in all metastases; 31% stained negative for PDGFRb, 86% negative for VEGFR and 45% negative for EGFR. Primary tumors revealed positive staining for PDGFRa in 88%, for PDGFRb in 59%, for VEGFR in 0% and for EGFR in 18%. Our investigation of a pilot character represents a 'biomarker-based' analysis of pulmonary metastases of different primary tumors; we conclude that an immediate 'tumor profiling' at initial diagnosis should be considered in order to guide tumor therapy individually.
Introduction
Tyrosine kinases (TK) and their receptors we.g. vascular endothelial growth factor receptor (VEGFR), platelet derived growth factor receptor (PDGFR) a and b and epidermal growth factor (EGFR)x mediate miscellaneous physiological actions, such as angiogenesis, endothelial cell migration and differentiation and vascular permeability w1x. Dysregulation of TKs implies overexpression, mutation and fusion to partner proteins w2x. In various human cancers, tyrosine kinase receptors (TKRs) are overexpressed and related to metastasation and poor survival w3x. As angiogenesis is crucial for tumor growth blockade of these receptors is an attractive tool in cancer treatment and has been established in antitumor therapy w4x. Several inhibitors of tyrosine kinases (TKIs) have been introduced in cancer therapy and evaluated in the clinical setting as target therapy alone or in combination with conventional chemotherapy. In the treatment of advanced renal cell cancer, metastasized colorectal cancer and non-small cell lung cancer target therapy with TKIs showed encouraging results w4, 5x. Yet, this approach failed to produce improved clinical outcome in a larger proportion of the treated patients. One hypothesis for this phenomenon is that patients are disease but not biomarker selected w6x. The *Corresponding author. Tel.: q49-731-500-54044; fax: q49-731-500-26748. E-mail address: bernd.muehling@uniklinik-ulm.de (B.M. Muehling).
lung is a frequent metastatic site of various tumors and patients developing pulmonary metastases are offered target therapy in the second line; yet, results in this context are bad which might be attributed to the fact that candidate targets are not expressed in the primary tumor or its metastases to be treated. To our knowledge, the expression pattern of candidate targets in pulmonary metastases has not yet been studied. Hence, the aim of our investigation was to characterize the expression pattern of receptors for VEGFR, PDGFRa and b and EGFR in pulmonary metastases and paired primary tumors. 
Materials and methods

Patient characteristics
TKR, tyrosine kinase receptor; PDGFR, platelet derived growth factor receptor; VEGFR, vascular endothelial growth factor receptor; EGFR, epidermal growth factor receptor. 
Immunohistochemistry
Paraffin embedded tissue sections were subjected to immunostaining using the streptavidin-peroxidase technique. Briefly, silanized slides were washed three times for 5 min in xylol and subsequently submerged in decreasing concentrations of isopropanol (100, 80, 70 and 50%) to remove alcohol in tissue samplings. After washing in PBS (3 times for 10 min) tissue slides were incubated with 2% normal serum for 20 min. Subsequently, primary antibodies against each TKR were added to the tissue slides: VEGFR2 polyclonal mouse antibody dilution 1:100 with pronase pretreatment (Acris, Herford, Germany); PDGFRa polyclonal rabbit antibody anti-human, dilution 1:100 with antigen retrieval by microwave treatment in citrate buffer pH6 (Dianova, Hamburg, Germany); PDGFRb polyclonal rabbit antibody anti-human; dilution 1:100 with antigen retrieval by microwave treatment in citrate buffer pH6 (Dianova Hamburg, Germany); EGFR wMouse anti-human monoclonal antibody 2-18C9; dilution 1:100 with pronase pretreatment (Dako, Glostrup, Denmark)x. Tissue slides were incubated with the specific antibody overnight at 4 8C. The following day they were washed three times with PBS and then incubated for 40 min with the biotinylated secondary antibody (from Dako). Repeated washing with PBS was followed by incubation streptavidin-biotinylated peroxidase solution for 40 min. Hereafter, sections were washed again with PBS before they were stained with DAB for 15 min. After washing in distilled water for 10 min, sections were counterstained in 30% H.E. Finally, the slides were washed in increasing concentrations of isopropanol (50, 70, 80 and 100%) followed by submerging in xylol for three times.
Quantitation of immunohistochemistry
Quantitation of the stainings was performed by two senior pathologist (T.F.E.B., C.H.) based on the scoring system provided by DAKO ( Table 2) . Table 3 shows the expression of the investigated TKRs in the pulmonary metastasis. All mets stained positive for PDGFRa with weak to moderate expression in 40% of the cases. One-third of the mets stained negative for PDGFRb; the majority stained negative for VEGFR. Detailed information is depicted in Table 3 , Fig. 1. 
Results
Expression of TKRs in pulmonary metastasis
Expression of TKs in primary tumors
In 17 patients primary tumors were available. Of these the majority stained negative for VEGFR in 85%; all available primary tumors stained positive for PDGFRa (Table 4) .
Discussion
This report describes the IHC expression pattern of VEGFR, PDGFRa and b and EGFR in a series of 35 pulmonary metastases. As many types of cancer show overexpression of these receptors, TKIs have become an attractive target in anti-cancer therapy w4, 5x. However, treatment studies failed to improve clinical outcome which indicates the necessity of better criteria for patient selection. Several TKR, tyrosine kinase receptor; PDGFR, platelet derived growth factor receptor; VEGFR, vascular endothelial growth factor receptor; EGFR, epidermal growth factor receptor. reasons for bad clinical response are discussed in this context: i) intratumoral heterogeneity of TKR expression which has been described in colonic cancer w7x, and ii) specific mutations in TKs which seem to determine the response to TKI therapy w4, 8x. As a consequence, patients of various disease entities scheduled for target therapy should be stratified according to the expression of specific biomarkers w6x. Patients developing metachronous pulmonary metastases after initial surgical removal and additional chemotherapy of a malignant tumor are candidates for second line chemotherapy including TKIs. The expression of platelet derived growth factor and its receptor by tumor cells, tumor associated endothelial cells and pericytes is common in many neoplasms and has already been described w9x. In hepatocellular and colonic carcinoma the expression of PDGF and its receptors is correlated to metastatic potential w10x; this is in line with our findings since PDGFRa was expressed in all pulmonary metastases with no difference depending on tumor size, nodal status and grading. Accordingly, the majority of the available paired primary tumors stained positive for PDGFRa (88.3%). As for PDGFRb we had positive staining in primary tumors in 59% and in pulmonary metastases in 69%. Another attractive target for TKI is the VEGFR. VEGF contributes to cell migration, proliferation of endothelial cells and induces angiogenesis in vivo. Increased levels of VEGF have been associated to various respiratory disorders, such as ARDS, COPD and lung cancer w11x. In NSCLC, 46% of tumors show high VEGF immunoreactivity which is considered a significant prognostic factor w12x; moreover, co-expression of VEGF and COX-2 is associated with lymphangiogenesis and prognosis in breast cancer w13x. In our series only 14% of pulmonary mets and none of the primary tumors stained positive for VEGFR; as for EGFR which is highly expressed in solid tumors, including oral cancer, we found negative staining in 45% of pulmonary metastases and in 82% of paired primary tumors. Patients with larger tumors and higher nodal status showed higher expression rates of EGFR (data not shown); however, other groups found no significant correlation between EGFR expression and tumor stage, regional lymph node metastasis and distant metastasis w14x.
In an immunohistochemical analysis of brain metastasis from NSCLC by Milas and co-workers it was found that brain metastases from lung cancer expressed EGFR in 59% of the cases w15x. Moreover, EGFR expression in primary tumors showed no correlation to patient survival w15x.
In summary, our immunohistochemical study of lung metastases and paired primary tumors revealed weak to moderate expression of PDGFRa in all and negative staining of VEGFR in the majority of metastases. These findings emphasize the tumor heterogeneity which may in part explain the bad clinical success of target therapies. Our data support a precise analysis of angiogenic and other factors in malignant tumors as well as their metastases prior to initiating specific therapies; in the clinical setting immunohistochemical assessment -which is easily available -can reveal the expression pattern of potential targets; subsequently, a closer analysis of the target e.g. by identification of somatic mutations should be performed in order to complete a precise 'tumor profiling' and to estimate the response to target therapy. By this means tumors can be analyzed individually on the basis of relevant biomarkers which would guide chemotherapy and avoid unnecessary, toxic and unsuccessful therapy.
